TrivarX has locked in investigational product supply critical for starting its Phase 1 clinical trial of the Stabl-Im MRI imaging platform, targeting a 2026 trial commencement.
- Investigational product supply secured for Phase 1 trial
- Trial aims to generate human safety and imaging data
- Stabl-Im offers non-radioactive tumour biology imaging
- Clinical trial prep includes protocol finalisation and site engagement
- Trial start depends on regulatory and ethics approvals
Milestone Achieved in Clinical Development
TrivarX Limited (ASX:TRI) has secured the investigational product supply needed to launch the Phase 1 clinical feasibility trial of its Stabl-Im imaging platform, marking a pivotal step in its clinical development strategy. This supply milestone underpins the company’s goal of commencing clinical activity within calendar year 2026.
Trial Focus and Design
The upcoming Phase 1 study is designed to assess the safety of Stabl-Im in humans while generating preliminary data on its clinical feasibility and imaging performance. The trial will provide an initial human evaluation of this MRI-based functional imaging technology, which uses stable isotopes to map tumour biology without radioactive tracers.
Innovative Imaging Without Radioactivity
Stabl-Im aims to enhance tumour assessment by delivering biologically meaningful insights into tumour activity, cell proliferation, and treatment response through existing MRI infrastructure. This approach could complement current standard-of-care imaging modalities by offering non-invasive, radiation-free functional data.
Ongoing Preparations and Partnerships
Alongside securing product supply, TrivarX has engaged Beyond Drug Development, a specialist contract research organisation, to support finalising the clinical protocol, preparing regulatory documentation, and identifying clinical sites. The company is progressing through regulatory, ethics, and operational steps necessary for trial initiation, with commencement contingent on approvals.
Leadership Perspective
CEO Dr Danielle Meyrick described the supply milestone as a critical achievement in executing the clinical development plan for Stabl-Im. She emphasised the study’s role in expanding human safety data and providing early evidence of the platform’s clinical utility. Dr Meyrick highlighted Stabl-Im’s potential to offer valuable tumour biology insights without complicating clinical workflows.
Bottom Line?
TrivarX’s supply milestone advances Stabl-Im closer to clinical testing, but regulatory and site approvals remain key hurdles before trial launch.
Questions in the middle?
- How will regulatory and ethics approvals impact the trial timeline?
- What preliminary imaging performance data will emerge from the Phase 1 study?
- Could Stabl-Im’s non-radioactive approach shift standard tumour imaging practices?